Welcome to our dedicated page for Galera Therapeutics news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics stock.
Galera Therapeutics develops clinical-stage oncology therapeutics and reports corporate updates under the GRTX symbol. Company news has centered on its shift toward anti-cancer therapeutics following the completed acquisition of Nova Pharmaceuticals, including a pan-inhibitor of Nitric Oxide Synthase program studied in advanced breast cancer settings.
Recurring updates also cover Galera’s portfolio and capital structure, including the disposition of its dismutase mimetics assets such as avasopasem and rucosopasem, financing activity, stockholder voting matters, governance actions, and operating and financial results. Earlier company disclosures addressed clinical and regulatory matters for cancer-related product candidates and strategic alternatives for the business.
Obsidian Therapeutics and Galera Therapeutics (OTC: GRTX) agreed to merge in an all-stock transaction to form Obsidian Therapeutics, Inc. and seek Nasdaq listing as OBX. An oversubscribed private placement will provide $350 million expected to fund operations into H2 2028 and support multiple 2027 clinical data milestones for OBX-115.
The combined company will advance OBX-115 (engineered TIL therapy) in Phase 1 NSCLC and Phase 2/registration-enabling melanoma trials and continue to support Galera’s pipeline and contingent value rights.
Galera Therapeutics (OTC: GRTX) entered an asset purchase agreement with Toronto-based Biossil for its dismutase mimetics portfolio, including avasopasem and rucosopasem.
Terms include an upfront $3.5 million payment and potential regulatory, commercial, and contingent payments totaling up to $105 million. Biossil will assume obligations under the 2018 Royalty Agreement, including a 4% royalty if either agent is commercialized. Galera will continue to advance its lead pan-NOS inhibitor (L-NMMA/tilarginine) in a multicenter Phase 2 trial for metaplastic breast cancer.
Notable data: a 407-patient Phase 3 of avasopasem showed a 16% relative reduction in severe oral mucositis (p=0.045) and a 56% reduction in SOM duration (p=0.002); FDA granted Fast Track and Breakthrough designations for avasopasem.
Galera Therapeutics (OTC: GRTX) has completed the acquisition of Nova Pharmaceuticals, shifting its focus to anti-cancer therapeutics with three trials targeting resistant breast cancer types. The company's lead program is a Phase 1/2 trial of Nova's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor combined with standard treatments for metaplastic breast cancer.
A syndicate led by Ikarian Capital invested $3 million in Galera common stock. The company's cash balance is expected to fund operations through its lead program data readout and into 2026. Additional trials include a TNBC study with the I-SPY 2 consortium and an Avasopasem trial in hormone-receptor positive advanced breast cancer, scheduled to begin in H1 2025.
Galera Therapeutics (Nasdaq: GRTX) announced its Board's approval of a Plan of Liquidation and Dissolution, seeking stockholder approval on October 17, 2024. If approved, the company will file for dissolution with Delaware and distribute remaining cash to stockholders after settling liabilities. This decision follows a year-long review of strategic alternatives to maximize stockholder value. Galera will reduce its workforce to three employees by August 31, 2024, with the CEO continuing through the transition.
In Q2 2024, Galera reported:
- Research and development expenses: $1.4 million (down from $7.6 million in Q2 2023)
- General and administrative expenses: $2.8 million (down from $9.2 million in Q2 2023)
- Net loss: $(4.1) million, or $(0.07) per share
- Cash and cash equivalents: $10.7 million as of June 30, 2024
Galera Therapeutics, Inc. (Nasdaq: GRTX) reported financial results for Q1 2024, highlighting a net loss decrease compared to 2023. The company is exploring strategic alternatives to maximize shareholder value, potentially leading to dissolution. The Board adopted a Rights Agreement to protect stockholder interests. Galera had $13.5 million in cash as of March 31, 2024, expected to fund operations into Q3 2025.
Galera Therapeutics, Inc. adopts a duration stockholder rights agreement to protect stockholder interests in response to recent accumulations of the company's common stock. The agreement aims to enable all stockholders to realize the full potential value of their investment, reduce the likelihood of a person or group gaining control without paying an appropriate premium, and provide the Board with time to make informed decisions. The Rights Agreement will issue preferred share purchase rights to stockholders, with an expiration date of May 2, 2025. The agreement becomes exercisable if an acquiring person obtains ten percent or more of the company's common stock in an unapproved transaction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.